Genpharm provides fast-track market access to Rare Disease and specialty pharmaceutical companies looking to expand into the Middle East and North Africa (MENA) region. It is the regional leader in Rare Diseases and the only regional company to have Gene Therapy expertise.
Incorporated since 2012, a financially sound and privately owned company, Genpharm is based in the Dubai Science Park (DSP), U.A.E. It also has an office in Boston in the heart of the Biotech hub and in Ireland.
Operating through evidence-based medicine and the highest ethical standards, Genpharm provides its partners with fast and sustainable market access solutions into the MENA region. Genpharm employs highly qualified and experienced MSLs and KAMs. It offers regulatory, medical, PV and logistical support. Armed with knowledge of the local business culture and the vast network of trusted partners, Genpharm’s expertise allows it to create market opportunities for innovative healthcare products and services.
Current partners include Novartis Gene Therapy, Orchard Therapeutics, Sarepta, PTC, Ultragenyx, Biohaven, Sintetica, Admedus, ABiotics and others.
For more info on the Middle East Pharmaceutical market and Genpharm business model and services, kindly visit www.genpharmservices.com
pharmaceutical consultancy, pharmaceutical sales, pharmaceutical marketing, market access strategists, pharma consult, pharma services, marketing, pharma consultancy, orphan drugs, rare disease, genetic disease, middle east, specialty pharmaceuticals, early patient access, name patient sales, reimbursement, gene therapy, neuromuscular diseases, gcc, cell therapy, pharmaceutical market acess, metabolic & inborn error disease, hematology, ophtalmology